Malarone (Proguanil Hydrochloride, Atovaquone)

Atovaquone interferes with the parasite’s mitochondrial electron transport chain, collapsing its energy production, while proguanil is metabolized to cycloguanil, which blocks the parasite’s dihydrofolate reductase enzyme, inhibiting folate synthesis. The two agents act synergistically, producing rapid parasite killing and reducing the chance of resistance development.

The specific dose of Malarone is determined by the prescribing clinician based on the indication, patient weight, age, and local resistance patterns. Typical adult regimens involve one tablet daily, but the exact schedule, duration, and any adjustments for renal or hepatic impairment must be set by a qualified healthcare provider.

Safety data for atovaquone/proguanil in pregnancy are limited, and the drug is generally classified as contraindicated or to be used only when the potential benefit outweighs the risk. Breastfeeding mothers should consult their physician, as the medication may be excreted in breast milk and could affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Malarone. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with monotherapy agents such as chloroquine or mefloquine, Malarone offers a dual‑mechanism approach that reduces the risk of resistance and is generally well tolerated. It provides both prophylactic and therapeutic coverage, whereas some alternatives are limited to either prevention or treatment, and may have a higher incidence of neuropsychiatric side effects.

Malarone tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed. Do not refrigerate or freeze the tablets, as temperature extremes can affect their stability.

Malarone is taken orally with a full glass of water, preferably with a fatty meal to enhance atovaquone absorption. For prophylaxis, the tablet is usually started one to two days before entering a malaria‑risk area and continued for seven days after leaving. For treatment, it is taken as directed for the full prescribed course.

Although uncommon, serious adverse reactions can include severe skin disorders such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, hepatotoxicity manifested by elevated liver enzymes or hepatitis, and hemolytic anemia, particularly in patients with glucose‑6‑phosphate dehydrogenase deficiency. Prompt medical attention is required if any of these symptoms develop.

Malarone is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil, or any component of the formulation. Patients with severe renal or hepatic impairment, G6PD deficiency, or those taking interacting medications that significantly reduce drug levels should avoid use unless a healthcare professional determines that benefits outweigh risks.